Prime Therapeutics Unveils Groundbreaking Insights at AMCP Nexus 2025
Prime Therapeutics Unveils Groundbreaking Insights at AMCP Nexus 2025
EAGAN, Minn., Oct. 27, 2025 — In light of escalating health care costs, Prime Therapeutics is taking a significant leadership role by sharing data-driven insights at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025. This conference, held in National Harbor, Maryland from October 27 to 30, features Prime presenting five key research posters and leading educational sessions focused on pressing industry challenges such as cost management and clinical accessibility.
Steve Cutts, Chief Clinical and Specialty Officer at Prime, emphasized the importance of providing healthcare purchasers with factual insights that can facilitate improved affordability and health outcomes. He stated, "Patients and providers face unprecedented uncertainty and rising costs across the health care ecosystem, so it's our responsibility as a trusted partner to deliver fact-based insights that promote improved affordability, access and health outcomes."
Highlighted Research at AMCP Nexus 2025
Among the key contributions from Prime at the conference are several research posters that delve into various healthcare topics:
1. Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
This study assesses adherence rates among commercially insured adults with obesity who are not diagnosed with diabetes.
2. Trends in Real-World Persistence to Weight Loss GLP-1 Receptor Agonists from 2021 to 2024
This research showcases significant trends in treatment adherence and received a prestigious platinum award from AMCP.
3. Impact of a Medical Claims Automated GLP-1 Drugs Prior Authorization Program
Recognized with a gold award, this study evaluates the effective management of GLP-1 medications through automated systems.
4. Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention
This study also won a gold award and discusses the outcomes of pharmacist-led interventions on prescribing behavior.
5. Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies
Focusing on therapies for relapsed follicular lymphoma, this study investigates both costs and adverse effects.
The Importance of GLP-1 Research
Prime's commitment to studying GLP-1 medications highlights its position as an authority on the influence of these drugs in obesity treatment. Cutts noted, "Prime's ongoing study of GLP-1s has positioned our organization as a leading voice on the impact of these drugs in the treatment of obesity. Furthermore, we focus on improving persistence and addressing the healthcare costs tied to these therapies."
The recognition of Prime's researchers at AMCP Nexus serves as a testament to the organization's dedication to advancing pharmacy solutions that benefit both patients and healthcare providers.
Looking Ahead
For attendees of AMCP Nexus 2025, Prime Therapeutics has laid out a detailed agenda, featuring educational presentations and workshops on these cutting-edge studies. To learn more about Prime's research and insights from the event, you can visit the Prime newsroom.
About Prime Therapeutics
Prime Therapeutics LLC operates as a pharmacy solutions partner that strives to deliver savings, simplicity, and support to its customers and members. Serving millions across the country, Prime specializes in pharmacy benefit management, specialty and medical drug management, and state government solutions. The organization is dedicated to setting a new industry standard with a conflict-free approach that prioritizes holistic specialty experiences, modern technology, and a commitment to ethical practices beyond profits. For more information, visit PrimeTherapeutics.com or follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.